{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T22:10:33Z","timestamp":1720476633825},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>To describe recent advancements in diagnostic and therapeutic approaches to inclusion body myositis (IBM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Our understanding of the implications of anti-cytosolic 5\u2032-nucleotidase 1A autoantibody status in IBM and other diseases is increasing. Muscle imaging using magnetic resonance techniques and ultrasound is increasingly being performed and characteristic patterns of muscle involvement may help with diagnosis. Longitudinal imaging studies are likely to help with monitoring and as an outcome measure in clinical trials. Recent small-scale studies of Arimoclomol and Rapamycin have shown promising results and further investigation of these medications is ongoing. Exercise is likely to form an increasingly important facet of management of patients with IBM, but the optimal type of exercise programme to enrol patients in is not yet determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Antibody testing and muscle imaging results may improve our ability to diagnose IBM and the availability of effective disease modifying treatments targeting novel non-inflammatory pathways could soon become a reality. It remains the duty of those involved in the management of patients with IBM to facilitate involvement in clinical trials and other research studies.<\/jats:p><\/jats:sec>","DOI":"10.1097\/bor.0000000000000537","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T22:09:07Z","timestamp":1533161347000},"page":"644-649","source":"Crossref","is-referenced-by-count":3,"title":["Advances in the early diagnosis and therapy of inclusion body myositis"],"prefix":"10.1097","volume":"30","author":[{"given":"James B.","family":"Lilleker","sequence":"first","affiliation":[{"name":"Faculty of Biology Medicine and Health, Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester"},{"name":"Greater Manchester Neuroscience Centre, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Salford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"e004552","DOI":"10.1136\/bmjopen-2013-004552","article-title":"A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis","volume":"4","author":"Brady","year":"2014","journal-title":"BMJ Open"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2013-305690","article-title":"Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features","volume":"84","author":"Brady","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5\u2032-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5\u2032-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2017.07.002","article-title":"Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts","volume":"472","author":"Muro","year":"2017","journal-title":"Clin Chim Acta"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/01.bor.0000434665.75998.f5","article-title":"Biomarkers of inclusion body myositis","volume":"25","author":"Greenberg","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/art.40045","article-title":"Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum","volume":"69","author":"Rothwell","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.md.0000217525.82287.eb","article-title":"Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies","volume":"85","author":"O\u2019Hanlon","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jnnp-2014-310008","article-title":"Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement","volume":"87","author":"Goyal","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/annrheumdis-2017-212436","article-title":"Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis","volume":"77","author":"Yeker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.24919","article-title":"Pathomechanisms of anticytosolic 5\u2032-nucleotidase 1A autoantibodies in sporadic inclusion body myositis","volume":"81","author":"Tawara","year":"2017","journal-title":"Ann Neurol"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/ana.24920","article-title":"Inclusion body myositis pathogenesis: steady progress","volume":"81","author":"Greenberg","year":"2017","journal-title":"Ann Neurol"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/ker001","article-title":"Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis","volume":"50","author":"Cox","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2214\/AJR.17.17849","article-title":"Sporadic inclusion body myositis: MRI findings and correlation with clinical and functional parameters","volume":"209","author":"Guimaraes","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"R19-20230901","first-page":"441","article-title":"Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies","volume":"55","author":"Yao","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1474-4422(15)00242-2","article-title":"MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study","volume":"15","author":"Morrow","year":"2016","journal-title":"Lancet Neurol"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1212\/WNL.0000000000003337","article-title":"Evaluation of dysphagia by novel real-time MRI","volume":"87","author":"Olthoff","year":"2016","journal-title":"Neurology"},{"key":"R22-20230901","article-title":"Pattern of muscle involvement in inclusion body myositis: a sonographic study","author":"Albayda","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.ultrasmedbio.2018.03.026","article-title":"Muscle shear wave elastography in inclusion body myositis: feasibility, reliability and relationships with muscle impairments","volume":"44","author":"Bachasson","year":"2018","journal-title":"Ultrasound Med Biol"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"e0184059","DOI":"10.1371\/journal.pone.0184059","article-title":"Automated diagnosis of myositis from muscle ultrasound: exploring the use of machine learning and deep learning methods","volume":"12","author":"Burlina","year":"2017","journal-title":"PLoS One"},{"issue":"(Suppl 10)","key":"R25-20230901","article-title":"A randomized, double-blind, placebo-controlled study of bimagrumab in patients with sporadic inclusion body myositis","volume":"68","author":"Amato","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"331ra41","DOI":"10.1126\/scitranslmed.aad4583","article-title":"Targeting protein homeostasis in sporadic inclusion body myositis","volume":"8","author":"Ahmed","year":"2016","journal-title":"Sci Transl Med"},{"key":"R27-20230901","article-title":"Rapamycin vs. placebo for the treatment of inclusion body myositis: improvement of the 6 min walking distance, a functional scale, the FVC and muscle quantitative MRI","volume":"69","author":"Benveniste","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","article-title":"Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes","volume":"25","author":"Mendell","year":"2017","journal-title":"Mol Ther"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.ymthe.2017.09.002","article-title":"Unfounded claims of improved functional outcomes attributed to follistatin gene therapy in inclusion body myositis","volume":"25","author":"Greenberg","year":"2017","journal-title":"Mol Ther"},{"key":"R30-20230901","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12883-016-0568-5","article-title":"Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM","volume":"16","author":"Schmidt","year":"2016","journal-title":"BMC Neurol"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"R32-20230901","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/brain\/aww024","article-title":"Association of inclusion body myositis with T cell large granular lymphocytic leukaemia","volume":"139","author":"Greenberg","year":"2016","journal-title":"Brain"},{"key":"R33-20230901","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2017.07.031","article-title":"Botulinum toxin alleviates dysphagia of patients with inclusion body myositis","volume":"380","author":"Schrey","year":"2017","journal-title":"J Neurol Sci"},{"key":"R34-20230901","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s10072-016-2586-x","article-title":"Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia","volume":"37","author":"Di Pede","year":"2016","journal-title":"Neurol Sci"},{"key":"R35-20230901","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/16501970306110","article-title":"Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction","volume":"35","author":"Arnardottir","year":"2003","journal-title":"J Rehabil Med"},{"key":"R36-20230901","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1600-0838.2006.00602.x","article-title":"Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity","volume":"17","author":"Fischer","year":"2007","journal-title":"Scand J Med Sci Sports"},{"key":"R37-20230901","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2119\/molmed.2010.00016","article-title":"A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis","volume":"16","author":"Nader","year":"2010","journal-title":"Mol Med"},{"key":"R38-20230901","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1249\/MSS.0b013e3181b18fb8","article-title":"Resistance training with vascular occlusion in inclusion body myositis: a case study","volume":"42","author":"Gualano","year":"2010","journal-title":"Med Sci Sports Exerc"},{"key":"R39-20230901","first-page":"1","article-title":"Blood-flow restricted resistance training in patients with sporadic inclusion body myositis: a randomized controlled trial","author":"J\u00f8rgensen","year":"2018","journal-title":"Scand J Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T21:49:08Z","timestamp":1720475348000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000537","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}